Crestecbio
1 known investors
Crestec Bio develops CTB211, a redox nanoparticle (polymer micelle carrying the TEMPO nitroxide radical scavenger) originally researched at the University of Tsukuba, designed to scavenge reactive oxygen species and protect neural cells. It is being developed as a therapeutic to reduce reperfusion injury after thrombectomy in ischemic stroke patients, with a focus on brain and organ disorders.
Investors · 1
Frequently asked questions
- What does Crestecbio do?
- Crestec Bio develops CTB211, a redox nanoparticle (polymer micelle carrying the TEMPO nitroxide radical scavenger) originally researched at the University of Tsukuba, designed to scavenge reactive oxygen species and protect neural cells. It is being developed as a therapeutic to reduce reperfusion injury after thrombectomy in ischemic stroke patients, with a focus on brain and organ disorders.
- Who are Crestecbio's investors?
- Crestecbio's investors include UntroD Capital.